Kesselheim AS - Search Results

1

Orphan Drug Designation and Exclusivity for "Same Drugs".

Hong P, Sarpatwari A, Kesselheim AS. Hong P, et al. Among authors: kesselheim as. J Law Med Ethics. 2019 Jun;47(2):347-349. doi: 10.1177/1073110519857293. J Law Med Ethics. 2019. PMID: 31298092 No abstract available.

2

Improving antibiotic markets for long-term sustainability.

Kesselheim AS, Outterson K. Kesselheim AS, et al. Yale J Health Policy Law Ethics. 2011 Winter;11(1):101-67. Yale J Health Policy Law Ethics. 2011. PMID: 21381513 No abstract available.

3

Off-label drug use and promotion: balancing public health goals and commercial speech.

Kesselheim AS. Kesselheim AS. Am J Law Med. 2011;37(2-3):225-57. doi: 10.1177/009885881103700202. Am J Law Med. 2011. PMID: 21847880 No abstract available.

4

The prevalence and cost of unapproved uses of top-selling orphan drugs.

Kesselheim AS, Myers JA, Solomon DH, Winkelmayer WC, Levin R, Avorn J. Kesselheim AS, et al. PLoS One. 2012;7(2):e31894. doi: 10.1371/journal.pone.0031894. Epub 2012 Feb 21. PLoS One. 2012. PMID: 22363762 Free PMC article.

5

Ethical considerations in orphan drug approval and use.

Kesselheim AS. Kesselheim AS. Clin Pharmacol Ther. 2012 Aug;92(2):153-5. doi: 10.1038/clpt.2012.92. Clin Pharmacol Ther. 2012. PMID: 22814660

6

Introduction: insights from a National Conference: "conflicts of interest in the practice of medicine".

Kesselheim AS, Orentlicher D. Kesselheim AS, et al. J Law Med Ethics. 2012 Fall;40(3):436-40. doi: 10.1111/j.1748-720X.2012.00676.x. J Law Med Ethics. 2012. PMID: 23061571 No abstract available.

7

Effect of financial relationships on the behaviors of health care professionals: a review of the evidence.

Robertson C, Rose S, Kesselheim AS. Robertson C, et al. Among authors: kesselheim as. J Law Med Ethics. 2012 Fall;40(3):452-66. doi: 10.1111/j.1748-720X.2012.00678.x. J Law Med Ethics. 2012. PMID: 23061573

8

Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980-2009.

Outterson K, Powers JH, Seoane-Vazquez E, Rodriguez-Monguio R, Kesselheim AS. Outterson K, et al. Among authors: kesselheim as. J Law Med Ethics. 2013 Fall;41(3):688-96. doi: 10.1111/jlme.12079. J Law Med Ethics. 2013. PMID: 24088160

9

Using a drug-safety tool to prevent competition.

Sarpatwari A, Avorn J, Kesselheim AS. Sarpatwari A, et al. Among authors: kesselheim as. N Engl J Med. 2014 Apr 17;370(16):1476-8. doi: 10.1056/NEJMp1400488. N Engl J Med. 2014. PMID: 24738666 No abstract available.

10

Life cycle of medical product rules issued by the US Food and Drug Administration.

Hwang TJ, Avorn J, Kesselheim AS. Hwang TJ, et al. Among authors: kesselheim as. J Health Polit Policy Law. 2014 Aug;39(4):751-80. doi: 10.1215/03616878-2743027. Epub 2014 May 19. J Health Polit Policy Law. 2014. PMID: 24842974

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

718 results

Search Page